Telaprevir News and Research

RSS
Experts must monitor new antiviral compounds for HCV treatment

Experts must monitor new antiviral compounds for HCV treatment

Series of new clinical trials confirm range of viable treatment options for HCV patients

Series of new clinical trials confirm range of viable treatment options for HCV patients

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Evaluating patients for genetic variations impacts adherence to antiviral therapy

Evaluating patients for genetic variations impacts adherence to antiviral therapy

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

New irreversible covalent approach to inhibit viral protease

New irreversible covalent approach to inhibit viral protease

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Novel therapies for HCV treatment can precipitate several changes: Report

Novel therapies for HCV treatment can precipitate several changes: Report

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C